- Secukinumab (Cosentyx) is associated with stable efficacy at 52 weeks in a majority of patients with moderate-to-severe psoriasis in post hoc analyses of the FIXTURE and CLEAR trials.
Why this matters
- This analysis adds further support for sustained efficacy of secukinumab.
- In the CLEAR trial at 52 weeks, 90.2% of patients showed stable efficacy without loss of response and 77.7% showed stable efficacy without reduction of response (compared with 74.2% and 59.9%, respectively, of patients who received ustekinumab (Stelara).
- In the FIXTURE trial at 52 weeks, 83.5% of patients showed stable efficacy without loss of response and 66.4% of patients showed stable efficacy without reduction of response (compared with 58.3% and 42.6%, respectively, of patients who received etanercept (Enbrel).
- Of patients who experienced loss of response, 50.0% (CLEAR trial) and 26.5% (FIXTURE trial) regained response by continuing secukinumab.
- CLEAR included 336 patients who received secukinumab and 339 who received ustekinumab.
- FIXTURE included 327 patients who received secukinumab and 326 patients who received etanercept.
- Response categories were defined based on Psoriasis Area and Severity Index reduction from baseline.
- Funding: Novartis Pharma GmbH
- Post hoc analysis limits statistical analysis and comparisons between trials.